A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Eli Lilly and Company
Study ID
NCT07202884
Phase
PHASE3
Status
Recruiting

Conditions

  • Urinary Incontinence,Stress

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Orforglipron — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally

Study Details

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron works in adult female participants with stress urinary incontinence (SUI) who have obesity or overweight. SUI is leaking urine during movement or activity such as coughing or exercising. Participation in the study will last about 58 weeks from screening to safety follow-up.

Key Dates

Start date
Sep 30, 2025
Status verified
Jun 2026
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
1,000 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Orforglipron (GZS1)
    Participants will receive orforglipron orally
  • Placebo Comparator: Placebo (GZS1)
    Participants will receive placebo orally
  • Experimental: Orforglipron (GZS2)
    Participants will receive orforglipron orally
  • Placebo Comparator: Placebo (GZS2)
    Participants will receive placebo orally

Primary Outcome Measure

Change from Baseline in Incontinence Episode Frequency (IEF) [ Time Frame: Baseline, Week 52 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    317-615-4559
  • Physicians interested in becoming principal investigators please contact

Locations (21)

FacilityCityStateZIPSite coordinators
University of Alabama -The Kirklin ClinicBirminghamAlabama35233
Gabriela Halder (PRINCIPAL_INVESTIGATOR)
AMR ClinicalMobileAlabama36608
Danilo Herrera (PRINCIPAL_INVESTIGATOR)
Urologic Surgeons of ArizonaMesaArizona85206
Kashif Alvi (PRINCIPAL_INVESTIGATOR)
Matrix Clinical ResearchLos AngelesCalifornia90057
310-424-5922
Peyman Banooni (PRINCIPAL_INVESTIGATOR)
Alarcon Urology CenterMontebelloCalifornia90640
Juan Alarcon (PRINCIPAL_INVESTIGATOR)
Prestige Medical GroupTustinCalifornia92780
Lamia Gabal (PRINCIPAL_INVESTIGATOR)
Colorado Clinical ResearchLakewoodColorado80228
303-996-9649
David Cahn (PRINCIPAL_INVESTIGATOR)
AMR ClinicalFort MyersFlorida33912
239-936-4421
Kevin Fleishman (PRINCIPAL_INVESTIGATOR)
Altus ResearchLake WorthFlorida33461
561-641-0404
Samuel Lederman (PRINCIPAL_INVESTIGATOR)
New Age Medical Research CorporationMiamiFlorida33186
305-596-9901
Joanna Bedell (PRINCIPAL_INVESTIGATOR)
Emerald Coast OBGYN Clinical ResearchPanama CityFlorida32405
Samuel Wolf (PRINCIPAL_INVESTIGATOR)
Teak Research ConsultsLawrencevilleGeorgia30043
Kamar Alabi (PRINCIPAL_INVESTIGATOR)
Arcturus Healthcare , PLC, Troy Internal Medicine Research DivisionTroyMichigan48098
248-312-0025
Neil Fraser (PRINCIPAL_INVESTIGATOR)
OB/GYN Associates of ErieEriePennsylvania16507
Michael Scutella (PRINCIPAL_INVESTIGATOR)
Clinical Research of PhiladelphiaPhiladelphiaPennsylvania19114
215-676-6696
Eugene Andruczyk (PRINCIPAL_INVESTIGATOR)
Innovative Medical Research of TexasHoustonTexas77065
Karyn Cumberbatch (PRINCIPAL_INVESTIGATOR)
Next Level Urgent CareHoustonTexas77057
832-460-3311
Wilner Jeudy (PRINCIPAL_INVESTIGATOR)
Health Research of Hampton Roads, Inc.Newport NewsVirginia23606
757-591-8100
George Freeman (PRINCIPAL_INVESTIGATOR)
Urology of VirginiaVirginia BeachVirginia23462
Kurt McCammon (PRINCIPAL_INVESTIGATOR)
Northwest Clinical Research CenterBellevueWashington98007
877-453-0404
Ann Kolwitz (PRINCIPAL_INVESTIGATOR)
Seattle Clinical Research CenterSeattleWashington98104
206-522-3330
Rebecca Dunsmoor-Su (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

Related Studies